A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation
研究概览
简要总结
This study of vitamin D is designed to assess both the safety and efficacy of potential doses (2,000 IU/day and 4,000 IU/day) in raising a vitamin D level to a normal range in a short period of time (e.g. 4 weeks or less) compared to 200 IU/day.
In children with vitamin D insufficiency or deficiency who are at risk for severe asthma exacerbations, we hypothesize that both vitamin D supplementation with 4,000 IU/day and 2,000 IU/day will safely achieve normal vitamin D levels, but that the higher dose (4,000 IU/day) will result in a larger proportion of subjects achieving this level at 4 and 8 weeks.
详细描述
Asthma is a major public health problem in the United States and worldwide. Severe disease exacerbations account for the majority of costs attributable to asthma in the United States. Vitamin D is an essential nutrient with significant immuno-modulatory effects. The observation that vitamin D insufficiency and asthma share risk factors such as urban residence, obesity, and African American ethnicity has generated significant interest in exploring a link between these two conditions.
This is an 8-week randomized, double-masked, controlled trial of vitamin D3 (2,000 IU/day and 4,000 IU/day) to achieve vitamin D sufficiency (a serum 25(OH)D ≥30 ng/ml in 60 school-aged children (ages 6 to 14 years) who have vitamin D insufficiency (a serum 25(OH)D <30 ng/ml) and are at risk for severe asthma exacerbations, but whose asthma that is well-controlled on medium-dose inhaled corticosteroid (ICS) at the end of a 4-week run-in period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 6 Years 至 14 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be at least 6 years of age and younger than 15 years of age
- •Have physician-diagnosed asthma
- •Taking a medium dose of ICS (e.g. fluticasone 220mcg BID) for daily asthma control for at least 6 months in the prior year.
- •Have had a severe asthma exacerbation in the previous year, defined as an Emergency Department (ED) visit, hospitalization, or unscheduled clinic visit for asthma resulting in intramuscular, intravenous, or oral steroids.
- •Have bronchodilator responsiveness (BDR, an increase in FEV1 ≥12% from baseline after administration of inhaled albuterol) or (if no BDR) increased airway responsiveness to methacholine challenge
- •Have vitamin D insufficiency (a serum vitamin D (25(OH)D) level <30 ng/ml)
- •Have his/her parents give voluntary written consent to participate in the study
排除标准
- •Chronic respiratory disorder other than asthma (e.g., bronchiectasis).
- •Severe asthma, as evidenced by any of the following: a) chronic need for medication other than single controller therapy and inhaled β2-agonist, b) intubation for asthma at any time, and c) ≥2 hospitalizations or ≥6 severe asthma exacerbations in the previous year
- •History of cigarette smoking in the prior year or former smoking if ≥5 pack-years
- •Hepatic or renal disease, metabolic rickets, malabsorptive disorders, or other chronic diseases that would affect vitamin D metabolism
- •Immune deficiency, cleft palate or Down's syndrome, which might increase the child's likelihood of respiratory infections
- •Treatment with anticonvulsants or pharmacological doses of vitamin D (≥1,000 IU/day of vitamin D2 or D3)
- •Chronic oral corticosteroid therapy
- •Inability to perform acceptable spirometry
- •Use of investigational therapies or participation in clinical trials 30 days before or during the duration of the study
- •Serum calcium >10.8 mg/dl
- •Serum 25(OH) D <10 ng/ml (severe vitamin D deficiency)
研究组 & 干预措施
Cholecalciferol 200 IU
Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
干预措施: Cholecalciferol (Dietary Supplement)
Cholecalciferol 2000 IU
Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
干预措施: Cholecalciferol (Dietary Supplement)
Cholecalciferol 4000 IU
Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
干预措施: Cholecalciferol (Dietary Supplement)
结局指标
主要结局
Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation
时间窗: 8 weeks
The primary outcome of the proposed trial will be a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation
Number of Participants With Vitamin D Sufficiency (Vitamin D ≥30 ng/ml) After 4 Weeks of Supplementation
时间窗: 4 weeks
The outcome is defined as the number of participants with a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation
次要结局
- Number of Participants With Vitamin D Toxicity(8 weeks)
- Number of Participants With Elevated Urinary Calcium/Creatinine Ratio(4 and/or 8 weeks)
- Number of Participants With FEV1 < 80% of Predicted(8 weeks)
研究者
Juan Celedon, MD
MD
University of Pittsburgh